Sarepta Therapeutics Inc  

(Public, NASDAQ:SRPT)   Watch this stock  
Find more results for NASDAQ:AVII
16.81
+0.29 (1.76%)
Nov 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.10 - 16.92
52 week 14.31 - 40.00
Open 16.67
Vol / Avg. 783,174.00/2.20M
Mkt cap 694.42M
P/E     -
Div/yield     -
EPS -2.54
Shares 41.31M
Beta 0.50
Inst. own 64%
Dec 10, 2014
Sarepta Therapeutics Inc at Oppenheimer Healthcare Conference - 11:30AM EST - Add to calendar
Dec 2, 2014
Sarepta DMD Community Update - 11:00AM EST - Add to calendar
Dec 1, 2014
Sarepta Therapeutics Inc at Deutsche Bank BioFEST - 8:05AM EST - Add to calendar
Nov 19, 2014
Sarepta Therapeutics Inc at Stifel Healthcare Conference - Webcast
Nov 11, 2014
Sarepta Therapeutics Inc at Credit Suisse Healthcare Conference - Webcast
Nov 6, 2014
Q3 2014 Sarepta Therapeutics Inc Earnings Release
Nov 6, 2014
Q3 2014 Sarepta Therapeutics Inc Earnings Call - Webcast
Oct 27, 2014
Sarepta Therapeutics Announces Regulatory Update on Eteplirsen Conference Call - Webcast
Oct 1, 2014
Sarepta Therapeutics Inc at Leerink Rare Disease Roundtable - Webcast
Sep 10, 2014
Sarepta Therapeutics Inc. at Morgan Stanley Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -2759.77% -787.57%
Operating margin -3179.89% -634.95%
EBITD margin - -625.97%
Return on average assets -35.72% -45.10%
Return on average equity -40.00% -60.39%
Employees 146 -
CDP Score - -

Address

SUITE 415, 215 FIRST STREET
CAMBRIDGE, MA 02142
United States - Map
+1-617-2744000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. Its product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. It is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). It initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.

Officers and directors

John C. Hodgman Interim Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Christopher Garabedian President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Sandesh Mahatme Chief Financial Officer, Senior Vice President, Chief Accounting Officer
Age: 49
Bio & Compensation  - Reuters
David Tyronne Howton Senior Vice President, General Counsel, Corporate Secretary
Age: 42
Bio & Compensation  - Reuters
Jayant Aphale Ph.D. Senior Vice President - Technical Operations
Age: 53
Bio & Compensation  - Reuters
Edward M. Kaye M.D. Senior Vice President, Chief Medical Officer
Age: 65
Bio & Compensation  - Reuters
M. Kathleen Behrens Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Anthony R. Chase Independent Director
Bio & Compensation  - Reuters
Gil Price M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Hans Wigzell M.D., Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters